Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Sept. 25, 2009 

Medicare Should Deny Payment for Knee Device That FDA Improperly Approved

FDA Investigation Found That Agency Managers Overruled Scientists After Political Pressure 

WASHINGTON, D.C. - Medicare should deny reimbursement for a knee device that the Food and Drug Administration (FDA) approved after political pressure from the manufacturer and members of Congress, Public Citizen said today in a letter sent to Medicare officials.

There is no proof that the Menaflex Collagen Scaffold device made by ReGen Biologics provides any clinical benefit for patients undergoing cartilage removal, Public Citizen said in the letter in which it opposed ReGen’s application to Medicare for a “national coverage determination.” Public Citizen made the sole public objection to the device when it was undergoing FDA review

An FDA internal investigation made public Thursday acknowledged undue pressure from four New Jersey members of Congress to approve the device and that the then-FDA commissioner took the unusual step of intervening in the process, subverting the customary FDA advisory committee processes.

Public Citizen’s letter reviewed a gold standard, randomized controlled trial in which the company compared patients undergoing cartilage removal and device implantation with cartilage removal alone. This trial provided no evidence of effectiveness on any of the three major clinical outcomes.

“Just as a physician would be hard-pressed to justify implanting a device not proven to have any clinical benefit, Medicare should be hard-pressed to justify reimbursing for it,” said Dr. Peter Lurie, deputy director of Public Citizen’s Health Research Group.

READ Public Citizen’s letter.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.